Background: The proliferation marker Ki67 has been suggested as a promising cancer biomarker. As Ki67 needs an exact quantification, this marker is a prototype of a new generation of tissue-based biomarkers. In this study, we have systematically evaluated different cut points for Ki67 using three different clinical end points in a large neoadjuvant study cohort.
As most studies have evaluated heterogeneous mixed cohorts, it is not clear if Ki67 is equally useful for prognostic and predictive approaches in different subtypes.
In this study, we evaluated pretherapeutic Ki67 as a predictive marker for response to neoadjuvant chemotherapy ( pCR) as well as a prognostic marker for disease-free (DFS) and overall survival (OS) in pretherapeutic core biopsies from the neoadjuvant GeparTrio trial. We carried out a new methodological approach using the cutoff finder algorithm [10] as well as molecular subtype radar diagrams (MSRDs).
patients and methods study population
In the neoadjuvant GeparTrio study (NCT00544765), patients with primary breast cancer were enrolled after given written informed consent. For details of eligibility criteria, see supplementary Method section, available at Annals of Oncology online.
evaluation of Ki67 in core biopsies
An overview is given in supplementary Figure S1 , available at Annals of Oncology online. The monoclonal antibody Ki67 (clone MIB-1, 1 : 50, DAKO, Hamburg, Germany) was used on an autostainer (Ventana, Tucson, USA). The staining was evaluated by experienced pathologists, for details see supplementary Method section, available at Annals of Oncology online.
cut points for Ki67 and statistical evaluation
Cut points for Ki67 were tested using the Cutoff Finder algorithm [10] . Based on the results for the three end points pCR, DFS and OS as well as results from previous studies (see discussion), we grouped Ki67 levels in three groups: low (≤15%), intermediate (15. 01%-35%) and high (>35%). SPSS version 19.0 (IBM, Ehningen, Germany) was used.
results baseline clinical data
The clinicopathological characteristics of the study cohort are shown in supplementary Table S1 , available at Annals of Oncology online. The median follow-up was 82.4 months for DFS and 91.0 months for OS.
systematic evaluation of cut points for Ki67
The analysis using the biostatistical tool Cutoff Finder [10] shows that a wide range of cut points for Ki67 were significant ( Figure 1 ). For pCR, 94 of 95 cut points corresponding to Ki67 values between 2.5% and 94.5% were significant ( Figure 1B ). For DFS, 48 of 94 different cut points were significant, corresponding to cut points between 5.5% and 46.5%. For OS, 58 of 94 tests were significant, corresponding to significant Ki67 cut point values in the range between 3.5% and 58.5%. Based on the results of all three end points and previous studies (see Discussion section), the following cut points were chosen for Hazard ratio (HR) for overall survival (OS) in dependence of cutoff point. The plots were generated using the biostatistical tool Cutoff Finder [10] . Figure 2 and Table 1 (upper part). The pCR rates of the groups with low, intermediate and high Ki67 were 4.2%, 12.8% and 29.0% (P < 0.0005, χ 2 test for trends), the odds ratios of the three groups were 1.00, 3.32 and 9.20 (P < 0.0005, logistic regression). These findings were still significant after adjusting for clinicopathological parameters (P < 0.0005, logistic regression, Table 1 ).
For DFS and OS, the three groups were also significant on univariate (DFS: P < 0.0005, OS: P < 0.0005) and multivariate analysis (DFS: P = 0.012, OS: P = 0.013).
Ki67 in different breast cancer subtypes
To easily compare predictive and prognostic effects of Ki67 for three different end points ( pCR, DFS, OS) in eight different molecular subtypes we have developed the MSRDs, as shown in Figure 3 . This allows easy visualization of biomarker data in subgroups based on HR and HER2 status, as well as in combined subgroups based on expression of both markers. The detailed univariate and multivariate analysis for the subgroups is shown in Table 1 . This comparison shows that Ki67 performs differently across molecular subtypes if analyzed as a predictive marker ( Figure 3A ) compared with analysis as a prognostic marker ( Figure 3B and C) .
As shown in Figure 3A , Ki67 significantly predicts pCR in six of eight subtypes with high significance (P-values from 0.003 to <0.0005) in most groups of HR-positive as well as HR-negative tumors. Only for the HER2-positive subtypes, the predictive power is rather low (one of three HER2-positive groups is significant with borderline significance).
For DFS and OS, Ki67 is significant as a prognostic marker in three of eight molecular subtypes ( Figure 3B and C) and adds prognostic information only in the HR-positive groups. For HRpositive tumors, low Ki67 is linked to a good DFS and OS. For triple-negative tumors, three groups with low, intermediate and high Ki67 are not significantly different for DFS and OS.
evaluation of Ki67 in pCR and non-pCR cases
We further carried out an explorative evaluation of Ki67 in separate groups of pCR and non-pCR cases ( Figure 4 ). For nonpCR patients, Ki67 was a significant negative prognostic factor for DFS and OS over a wide range of cut points. Interestingly, Ki67 was a positive prognostic factor for DFS and OS for patients with a pCR, although this was significant only for cut points between 20.5% and 28.5% (DFS) and between 22.5% and 24.5% (OS). These results suggest that an increased expression of Ki67 is an indicator of poor prognosis in patients who are not responding to chemotherapy, but an indicator of good prognosis in patients with response to chemotherapy.
discussion
In this study, we systematically evaluated Ki67 expression in a large cohort of breast carcinomas from a prospective Figure 2 . Evaluation of Ki67 expression in the complete cohort: comparison of three groups with low (≤15% stained cells), intermediate (15.1%-35% stained cells), and high (>35% stained cells) Ki67 levels for pathological complete response ( pCR) rates (A), P < 0.0005, χ 2 test for trends), disease-free survival (B), P < 0.0005, log-rank test) and overall survival (C), P < 0.0005, log-rank test).
original articles Annals of Oncology neoadjuvant clinical trial. Our analysis showed that a wide range of cut points was significant for various end points and subgroups. Therefore, the difficulties in defining cut points should not be seen as a limitation of the marker but point to a strength of Ki67. The performance of the marker in cut point analysis is dependent on the clinical end points, the type of therapy, the distribution of responders and nonresponders and the molecular subtypes. From a tumor biological point of view, Ki67 should be viewed as a continuous variable, as it reflects the percentage of proliferating cells in the tumor, which can reach any value between 0 and 100%. It should be pointed out for clinical decisions that for any selected cut point, Ki67 values that are very closed to each other, but on both sides of the cut point, will reflect a very similar biological behavior. Therefore, the interpretation of Ki67 values that are very close to a cut point should be done with caution.
For a detailed analysis of different molecular tumor subgroups in our study, we have therefore decided to use two arbitrary cut points that separate three groups with low, intermediate and high Ki67 expression. We would like to point out that these arbitrary groups are not the result of a cut point optimization, which is not possible due to the similarity of the odds ratios for different cut points. However, these selected groups have several advantages for the further analysis: (i) Identical cut points could be used for the three end points pCR, DFS and OS. (ii) The cut points resulted in three groups, each with approximately one third of the samples in our study. (iii) The three cut points are similar to the suggestion included in the St Gallen 2009 guidelines [8] .
(iv) The 15% cut point is also comparable to the cut point suggested in the St Gallen 2011 guidelines [7] . (v) The identical cut points were used in a separated, but parallel investigation evaluating Ki67 in residual tumor after neoadjuvant chemotherapy [11] .
It is obvious from Figure 1 , however, that many other cut points would be suitable as well, which explains the different results of many previous studies and the inability of the scientific community to define a data-derived single cutoff for Ki67, so far. Therefore, it seems unlikely that a combined international approach will be able to define a data-derived cut point for Ki67. This leaves two options; based on the suggestions of the Ki67 Working Group [9] : (i) use Ki67 as a continuous parameter, (ii) use arbitrary cut points. The multiple valid cut points suggest that Ki67 might not be an optimal marker for subtype definition as suggested by the St Gallen panel 2011 [7] . This marker reflects the proliferative activity as a continuum; therefore other, gene-expression-based approaches including the activity of the HR-signaling pathways might be more suitable to define luminal A and B tumors. Multivariate analysis adjusted for age (gr40), cT1-3 versus cT4, cN0 versus cN1, lobular histology versus others, G1,2 versus G3, BL_HER2 status; BL_HR status, for analysis of subgroups: the parameter that defines group is not included.
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Limitations of our study include its retrospective character. Furthermore, all patients received chemotherapy, therefore the predictive and prognostic results are limited to a chemotherapytreated cohort, and trastuzumab was not given as part of the neoadjuvant treatment. For GeparTrio, only tumors with a comparably high risk have been selected, which has influence on the distribution of Ki67. In particular, the percentage of tumors with low Ki67 is higher in population-based cohorts. In a recent large population-based study, 50%-60% of tumors had a Ki67 of 0-15% [12] . Seven of nine previous neoadjuvant studies have reported a predictive role for either clinical or pathological response (reviewed in [4] ). A recent study investigating a retrospective neoadjuvant cohort of 552 patients has suggested that higher cut points might be more suitable [13] . In addition, several studies have shown that the short-term reduction of Ki67 after 2 weeks of therapy is predictive of outcome of endocrine therapy [14, 15] .
The analysis of Ki67 in different centers is subject to a relevant variance [16, 17] . We have tried to address this issue in our study by using a stringent monocentric evaluation with 
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exact counting of cells rather than semiquantitative estimations. Additionally, we are currently working on the development and the clinical validation of image-analysis-based approaches. The role of Ki67 in different molecular subtypes has not been evaluated to a great extent. In our study, we show that Ki67 is predictive for response to neoadjuvant therapy in nearly all molecular subtypes. This is explained by the fact that highly proliferative tumors respond better to neoadjuvant chemotherapy. Evaluating the prognostic role of Ki67 using the end points DFS and OS, the picture becomes more complicated. On one hand, Ki67 is a strong prognostic marker in the complete cohort for both DFS and OS. This stable prognostic role in cohorts with heterogeneous molecular subtypes is caused (i) by the increased Ki67 levels of the poor-prognosis HRnegative tumors and (ii) by the prognostic role of Ki67 in the large group of HR-positive tumors. In this group, patients with Ki67-positive tumors have a reduced survival. Because pCR and survival are linked in tumors treated with chemotherapy, those HR-negative tumors with intermediate and high Ki67 have an improved survival outcome due to the higher response rate to chemotherapy. Therefore, Ki67 has no prognostic effect in the HR-negative subgroup, despite the significant correlation with pCR.
These results point to a general problem in the development of molecular biomarkers, in particular if survival data are used for predictive evaluations. An excellent prognosis of a group of patients could be due to a highly effective therapeutic approach, but could also be caused by an excellent prognosis of the tumor, which is not related to the therapeutic intervention. A molecular biomarker could play a different role in both clinical situations, and the overlap of the different effects would lead to inconsistent results. This is exemplified by the explorative analysis of the pCR and non-pCR patients as separate groups. In the non-pCR group, increased Ki67 is a strong negative prognostic marker with a wide range of possible cut points, as expected. In the pCR group, however, increased Ki67 is a positive prognostic marker. This suggests that a response to chemotherapy could change the prognostic value of Ki67 to the opposite direction. This change can be detected in the neoadjuvant setting, but could cause problems for biomarker development and validation in the context of adjuvant studies, where survival outcome parameters are also used for evaluation of predictive markers. A strategy suggested by Hatzis et al. [18] to reduce this effect would be to exclude good-prognostic tumors from adjuvant chemotherapy trials based on molecular parameters such as gene expression tests to achieve a more homogenous trial population. Taken together, our study shows that Ki67 is significant for different end points and many different cut points. Based on our results, we suggest that the arbitrary definition of three subgroups for Ki67 (such as ≤15% versus 15.1%-35% versus >35%) could be a reasonable approach for further standardization of this marker by the scientific community.
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